Abstract
Purpose
We aimed to investigate the effectiveness of ferritin as a contrast agent and a potential reporter gene for tracking tumor cells or macrophages in mouse cancer models.
Materials and Methods
Adenoviral human ferritin heavy chain (Ad-hFTH) was administrated to orthotopic glioma models and subcutaneous colon cancer mouse models using U87MG and HCT116 cells, respectively. Brain MR images were acquired before and daily for up to 6 days after the intracranial injection of Ad-hFTH. In the HCT116 tumor model, MR examinations were performed before and at 6, 24, and 48 h after intratumoral injection of Ad-hFTH, as well as before and every two days after intravenous injection of ferritin-labeled macrophages. The contrast effect of ferritin in vitro was measured by MR imaging of cell pellets. MRI examinations using a 7T MR scanner comprised a T1-weighted (T1w) spin-echo sequence, T2-weighted (T2w) relaxation enhancement sequence, and T2*-weighted (T2*w) fast low angle shot sequence.
Results
Cell pellet imaging of Ad-hFTH in vitro showed a strong negatively enhanced contrast in T2w and T2*w images, presenting with darker signal intensity in high concentrations of Fe. T2w images of glioma and subcutaneous HCT116 tumor models showed a dark signal intensity around or within the Ad-hFTH tumor, which was distinct with time and apparent in T2*w images. After injection of ferritin-labeled macrophages, negative contrast enhancement was identified within the tumor.
Until recently, medical imaging was mostly based on anatomical imaging. However, to address an increased diagnostic need for information related to functional imaging and metabolism, novel imaging approaches have been developed, namely molecular imaging. The advent of molecular imaging can be attributed to the following factors: rapid advances in the field of biotechnology, encompassing various overlapping fields, such as cell biology, genetics, bioinformatics, and proteomics; and the merger between chemistry and nanotechnology.
Molecular imaging differs from indirect experimental approaches and those that rely on microscopic images. The results of the latter approaches are based on laboratory findings and analyses at the molecular or cellular levels to investigate cellular and pathological phenomena, whereas molecular imaging provides a more intuitive approach to gaining insight into disease pathophysiology and cellular mechanisms through in vivo real-time imaging.12 These types of molecular imaging include magnetic resonance imagining (MRI),345678 nuclear imaging,9 and optical imaging,10 and each has their own benefits and limitations. Of these, MRI offers with strong advantages, such as the highest resolution and tissue contrast, and being a noninvasive imaging approach without exposure to radiation. However, compared to that of nuclear imaging or optical imaging, MRI shows low signal sensitivity.11 To increase the sensitivity of MRI, contrast agents, such as paramagnetic gadolinium- and super-paramagnetic iron-oxide-based agents, have been used.12 The inhomogeneity and bio-instability of these magnetic particles, which leads to poor signal enhancement, still contributes to the slow growth of molecular imaging technology; however, recent developments in nanotechnology have ushered in substantial advancements.1314
Molecular MRI includes cell targeting and tracking imaging. The former uses a targeted-probe to diagnose and treat tumors and inflammation, and the latter marks grafted cells so that their movement, proliferation, differentiation, and final fate can be traced for treatment purposes. For cellular MRI, the easiest method is the direct targeting of cells by an MR contrast agent; however, barriers, such as dilution and instability of the contrast agents, limit the quality of the imaging. Nonetheless, the use of a reporter gene has been shown to moderately increase specificity and allow for long-term labeling of target cells. Studies on MRI reporter genes have been undertaken to investigate effective, safe, and more specific imaging methods of cell targeting. However, the MRI reporter genes that have been used thus far, including tyrosine, transferrin receptor (TFR),15 transferrin, and beta-galactosidase, have failed to give reproducible MRI results.16 Remarkably, ferritin, a putative MRI reporter gene, was shown to be associated with a high reproducibility for cellular MRI.171819
Ferritin is an intracellular metalloprotein, comprising a light and a heavy polypeptide chain, and binds to free iron.20 In spite of a low intracellular iron concentration, ferritin is an endogenous nanoparticle that shows a high, intrinsic magnetic property21 that is sustained without the need of an external contrast agent. Thus, ferritin may prove to be a very effective and safe MR contrast agent for cell tracking imaging.1922
This study aims to outline the effectiveness of ferritin as a contrast agent and potential reporter gene for tracking tumor cells and macrophages in mouse models of cancer.
For labeling of macrophage cells, ferritin from equine spleen was purchased from SIGMA Inc. (cat no. F4503). To verify the function of ferritin as a reporter gene, high-titer adenovirus (2×1011 PFU/mL) of adenovirus 5-human ferritin heavy chain (AD5-hFTH)-GFP was purchased from Vector Biolabs (Vector Biolabs, Malvern, PA, USA). The adenoviral vector was designed so that GFP expression was able to reflect adenoviral transduction and hFTH expression.
All cell lines used in this study were purchased from American Type Culture Collection. RAW264.7, a murine macrophage cell line, was maintained in RPMI medium supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Invitrogen). U87MG, a human glioblastoma cell line, and HCT116, a human colon cancer cell line, were maintained in DMEM containing 10% FBS and 1% penicillin/streptomycin. All cells were maintained in a humidified incubator at 37℃ with 5% CO2.
For measurement of the effect of ferritin-mediated MR contrast in cells, RAW264.7 cells (5×106) were incubated with equine ferritin, at a working concentration of 5 mg/mL, in serum-free medium. For U87MG cells, 3×106 cells were infected with 2×108 PFU adenovirus encoded hFTH and Mock for 48 h in complete medium containing FeCl3 at the indicated concentrations at 37℃ with 5% CO2. After incubation, all cells were collected by centrifugation at 2000 rpm and washed with phosphate-buffered saline (PBS) three times. Cells were transferred to 0.2 mL thin wall strip tubes, centrifuged, and MRI measurements were taken using the cell pellets.
The animals used in this study were kept under specific-pathogen-free conditions and maintained in a National Cancer Center animal facility in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care International Animal Care policy (accredited unit; National Cancer Center Research Institute; unit number 1392). Treatments in this study were performed in accordance with an experimental proposal (No. NCC-10-136, NCC-13-163B and 15-NCCIBC-002).
Six-week-old female BALB/c nude mice were purchased from Central Lab Animal Inc. (Seoul, Korea), and U87MG cells (3×105) were intracranially injected into the right brain of mice following care for two weeks with MRI every four to five days. Briefly, 14 days after inoculation with the U87MG cells, the mice were intracranially injected with 2×108 PFU of Ad-hFTH into the tumor region. Histological studies and MRI experiments were performed at each indicated time point.
HCT116 cells (3×106) were subcutaneously injected into the flanks of mice following care for roughly two weeks. The mean tumor volume was roughly 100 mm3. To verify the efficiency of ferritin as a reporter gene, mice were intratumorally injected with 5×108 PFU of Mock or Ad-hFTH in into each left and right tumor site, respectively. To track macrophages containing ferritin, RAW264.7 cells (5×106), previously incubated with equine ferritin (5 mg/mL) for 24 h, were intravenously injected into mice followed by MRI at each indicated time point.
The animal was sedated with 1–3% isoflurane through a nose cone. Its core temperature was monitored by a rectal thermistor and maintained at 37℃ by a flow of warm air. An electrocardiogram (ECG) was also taken by attaching a pair of sub-dermal needle electrodes. In order to suppress artifacts associated with motion, respiratory motion was monitored using an air pillow.
All experiments were performed using a 7T MRI (BioSpec 70/20, Bruker, Germany) with T1-, T2-, and T2*-weighted (T2*w) imaging techniques. A 35-mm-diameter quadrature birdcage-type radiofrequency coil (RF coil) was used for imaging of the subcutaneous cancer. For brain imaging of the model animals, a combination of the four-channel arrayed surface-type receive-only RF coil and 72-mm-diameter transmit-only RF coil was used.
MRI examination was performed for brain cancer model animals, which involved the T1-weighted (T1w) spin echo sequence and T2-weighted (T2w) rapid acquisition with relaxation enhancement (RARE) sequence. Imaging parameters were repetition time (TR)=800 ms (T1w)/2500 ms (T2w); echo time (TE)=10 ms (T1w)/35 ms (T2w); 256×192 acquisition matrix; field of view (FOV)=2×2 cm; slice thickness=0.7 mm; RARE factor=8. T2*w images were obtained using fast low angle shot (FLASH) sequence with the following acquisition parameters: TR=200 ms; TE=4 ms; the geometry parameters used were the same as above.
The T1w spin-echo and T2w RARE sequences were performed for imaging the colon cancer model animals. The acquisition parameters were TR=700 ms (T1w)/2500 ms (T2w); TE=10.5 ms (T1w)/30 ms (T2w); 256×192 acquisition matrix; FOV=2×2 cm; slice thickness=0.7 mm; RARE factor=8.
For analysis of Fe uptake by ferritin, cryosections of colon cancer tissue were fixed with 4% formaldehyde, and then washed with distilled water four times. Before staining, 5% potassium ferrocyanide was mixed with 5% hydrochloric acid at a 1:1 ratio. Fixed specimens were incubated with the mixed solution for 1 hr at room temperature, washed with water four times, and counter stained with Fast Red. The slides were scanned using the Aperio Imagescope v10.2.2.2319 software (Buffalo Grove, IL, USA).
To investigate whether ferritin works as a reporter, as well as a contrast agent for MRI, we used the serotype 5 adenoviral expression system of Ad-hFTH. A non-replicable adenovirus with a bi-promoter for hFTH and GFP expression was designed to monitor the transduction efficiency of adenovirus by GFP expression (Fig. 1). To examine the contrast effect of ferritin in cells, U87MG cells were infected with Mock and Ad-hFTH and the signal intensity of MR was measured with cell pellets as described in the Materials and Methods. As a result, in vitro tube imaging by adenoviral hFTH in U87MG cells was obtained, visualized as darker signal intensities in higher concentrations of Fe on T2w and T2*w images (Fig. 2). These results suggest the utilization of ferritin for MR contrast.
To examine the effectiveness of ferritin as a reporter for MRI in vivo, when applied to an in vivo glioma model, from serial MRI of mice with injection of Mock and Ad-hFTH, T2w and T2*w images of mouse brain were acquired for six days (Fig. 3). Dark signal intensity at the periphery of the Ad-hFTH tumor appeared at one day after injection, which was distinct with time, and more apparent in T2*w images. There was no signal change around the Mock-injected tumor, with the exception of a linear low signal intensity suggestive of the injection site (Fig. 3B).
Next, we found that the ferritin-induced signal intensity was measured in a colon cancer cell mouse model using HCT116, a human colon cancer cell line, after intratumoral administration of 5×108 PFU adenovirus at the indicated time points (Fig. 4). T2w images of all four mice showed low signal intensity within the Ad-hFTH tumor that appeared at 6 hr post injection, and gradually enlarged at 24 and 48 hr. All mice showed obvious hFTH-induced negative contrast, compared to Mock-infected tumor. In two mice (#1 and 2), curvilinear dark signal intensity (white arrows, Fig. 4), presumed to be hemorrhage, in the periphery of the mass in 6 and 24 h post-injection images disappeared at 48 h.
Taken together, these data suggest the potential of ferritin as a reporter for MRI in cancer models.
To validate whether macrophage cells labeled with ferritin are suitable for cancer tracking, we performed in vivo MR imaging of ferritin-labeled RAW264.7 cells in a subcutaneous xenograft mouse model (Fig. 5). RAW264.7 cells were labeled with ferritin (5 mg/mL) and the signal intensity of MR was examined as described in the Materials and Methods. The T2w RARE images (TE/TR 40/200 ms) of the cell pellets showed dark signal intensity in the pellets of RAW264.7 cells with ferritin contrast, compared to that of the PBS control (Fig. 5A).
Subsequently, MR imaging of mice injected with ferritin-labeled RAW264.7 cells via their tail vein was performed (Fig. 5B and C). Two days after administration of RAW264.7 cells via intravenous injection, MR images of the flank tumor showed a faint dark spot within the tumor mass. The dark spots increased in number and were more distinct on day 4 post-injection of RAW264.7 cells. Next, to confirm the uptake of iron by ferritin, we performed Prussian blue staining of paraffin-embedded tumor sections. Multiple blue dots were observed near vessel structures, suggesting that macrophage cells containing ferritin-mediated iron were distributed (Fig. 5D). These results suggest that macrophage cells can be identified in cancer mouse models via the negative contrast effect of ferritin-labeling.
This study showed that negative T2 and T2* contrast enhancement can be identified in a FTH-expressing cancer mouse model by adenoviral gene delivery, suggesting that ferritin could be a potential candidate for a MR reporter gene in cell tracking imaging.
Meanwhile, for long-term cell tracking, the establishment of a stable cell line was predominantly attempted using lentiviral or retroviral expression systems. However, there were some limitations to the use of lentiviruses in this study. One major limitation was that infected cancer cells showed irregular expression levels due to a wide range of copy number variants and increased population of dead cells because of high-titer lentivirus-induced toxicity, and thereby, it required a sorting step and amplification periods for in vivo inoculation. The gene delivery vehicle, which is a determinant of transduction efficiency and safety, is a key element for successful expression. The serotype 5 adenovirus is the most favored gene delivery vehicle, which is currently being used extensively in more than 100 cancer gene therapy clinical trials across the world; adenoviruses have the advantage of being able to transduce in both dividing and non-dividing cells, amplify in high-titer easily, and they do not integrate into the host genome.23 The adenoviral vector used in this study was designed to monitor transduction efficiency through GFP expression, although the GFP expression level is not capable of reflecting hFTH expression perfectly, like the hFTH-IRES-GFP system. The commercially available adenovirus used in this study, the construction of which is shown in Fig. 1A, is able to generate high-titer adenovirus for in vivo use in small volumes, and minimize batch variation.
The hFTH expressed by the adenovirus triggered Fe uptake around inflammatory regions, such as those in cancer. We used macrophage cells known as tropism into the tumor, thereby we provide the evidence that ferritin-labeled macrophage cells are effective monitoring tools of tumor. Like macrophages, stem cells are known to have tumor tropism, as well as wound-related inflammation. Many people have suggested that mesenchymal stem cells may be useful as a gene delivery tool in cancer therapy. Gene delivery requires a tracking system to monitor targeting efficiency and predict therapeutic efficacy. The reporter gene system using ferritin could be a multi-detection system for tracking delivery vehicle locations, cancer regions, and stem cell fates, if adopted in stem cell-mediated gene delivery.24
Ferritin would be considered to function as the MR contrast agent. although the value of relaxivity (R2) is lower than that of commercially available T2 contrast agent, Feridex.25 Actually, the value of R2 of ferritin was measured as 0.00159 mL/µg Fe·1/sec, which is almost half of Feridex, at 0.00298 mL/µg Fe·1/sec (Supplementary Fig. 1, only online). Nevertheless, the R2 value of ferritin seems to be sufficient to act as the MR contrast agent for cellular imaging. Contrast agents based on superparamagnetic particles are in clinical development. Relaxivities are frequently used to give an idea of their efficacy; however, these parameters can only be used if they are concentration independent.26 Usually, superparamagnetic iron oxide nanoparticles can be utilized to label cells.1127 In conventional MRI with superparamagnetic particles, the signal voids arising from the field distortions lead to negative contrast, which is not desirable, as the detection of cells can be masked by native low signal tissue. Additionally, it is difficult to quantify the concentration of the superparamagnetic particles. In order to overcome the negative contrast from the superparamagnetic iron oxide nanoparticles, many imaging techniques have been developed, including positive contrast imaging, susceptibility-weighted imaging, and susceptibility mapping.2829 In positive contrast imaging, the signal is obtained from off-resonance spins around the superparamagnetic iron oxide nanoparticles. The strong field distortion from the superparamagnetic particles can be detected by exciting off-resonance spins.
For susceptibility-weighted imaging and susceptibility mapping, complicated bundles of image post-processes, such as a phase map, are used after the MRI scan. Many studies have reported on more accurate maps and faster calculations. The algorithms for image post-processing are still controversial among many research groups. Due to the complexity and controversy of the quantification, superparamagnetic particle quantification was not applied to the analysis of the animal images in this study. Further investigations of quantitative MRI technique are needed.
In conclusion, through cellular level investigation and in vivo experiments using animal models, this study strongly suggests the effectiveness of ferritin as an endogenous MR contrast agent and as a potential reporter gene that is capable of maintaining cell labeling stability and cellular safety.
ACKNOWLEDGEMENTS
We would like to thank the Molecular Imaging Core in the Korea National Cancer Center for assistance with the in vivo imaging. This study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of National Cancer Center Research Institute. NCCRI is an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International) accredited facility and abide by the Institute of Laboratory Animal Resources (ILAR) guide. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MISP) (No. 2010-0028684), by the National Cancer Center Grants (NCC1410040) and by the grant of the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C1627 to HS-K).
References
1. Brader P, Serganova I, Blasberg RG. Noninvasive molecular imaging using reporter genes. J Nucl Med. 2013; 54:167–172. PMID: 23318292.
2. Youn H, Chung JK. Reporter gene imaging. AJR Am J Roentgenol. 2013; 201:W206–W214. PMID: 23883235.
3. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med. 2000; 6:351–355. PMID: 10700241.
4. Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A Jr. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem. 2002; 13:122–127. PMID: 11792187.
5. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Noninvasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001; 7:1241–1244. PMID: 11689890.
6. Artemov D. Molecular magnetic resonance imaging with targeted contrast agents. J Cell Biochem. 2003; 90:518–524. PMID: 14523986.
7. Huh YM, Jun YW, Song HT, Kim S, Choi JS, Lee JH, et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc. 2005; 127:12387–12391. PMID: 16131220.
8. Jun YW, Huh YM, Choi JS, Lee JH, Song HT, Kim S, et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc. 2005; 127:5732–5733. PMID: 15839639.
9. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002; 53:89–112. PMID: 11818465.
10. Graves EE, Weissleder R, Ntziachristos V. Fluorescence molecular imaging of small animal tumor models. Curr Mol Med. 2004; 4:419–430. PMID: 15354872.
11. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004; 17:484–499. PMID: 15526347.
12. Ahn SJ, Koom WS, An CS, Lim JS, Lee SK, Suh JS, et al. Quantitative assessment of tumor responses after radiation therapy in a DLD-1 colon cancer mouse model using serial dynamic contrast-enhanced magnetic resonance imaging. Yonsei Med J. 2012; 53:1147–1153. PMID: 23074115.
13. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007; 13:95–99. PMID: 17187073.
14. Song HT, Choi JS, Huh YM, Kim S, Jun YW, Suh JS, et al. Surface modulation of magnetic nanocrystals in the development of highly efficient magnetic resonance probes for intracellular labeling. J Am Chem Soc. 2005; 127:9992–9993. PMID: 16011350.
15. Pawelczyk E, Arbab AS, Pandit S, Hu E, Frank JA. Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed. 2006; 19:581–592. PMID: 16673357.
16. Gilad AA, Winnard PT Jr, van Zijl PC, Bulte JW. Developing MR reporter genes: promises and pitfalls. NMR Biomed. 2007; 20:275–290. PMID: 17451181.
17. Cohen B, Ziv K, Plaks V, Israely T, Kalchenko V, Harmelin A, et al. MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med. 2007; 13:498–503. PMID: 17351627.
18. Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med. 2005; 11:450–454. PMID: 15778721.
19. Uchida M, Terashima M, Cunningham CH, Suzuki Y, Willits DA, Willis AF, et al. A human ferritin iron oxide nano-composite magnetic resonance contrast agent. Magn Reson Med. 2008; 60:1073–1081. PMID: 18956458.
20. Carrondo MA. Ferritins, iron uptake and storage from the bacterioferritin viewpoint. EMBO J. 2003; 22:1959–1968. PMID: 12727864.
21. Gossuin Y, Muller RN, Gillis P. Relaxation induced by ferritin: a better understanding for an improved MRI iron quantification. NMR Biomed. 2004; 17:427–432. PMID: 15526352.
22. Kim HS, Woo J, Lee JH, Joo HJ, Choi Y, Kim H, et al. In vivo tracking of dendritic cell using MRI reporter gene, ferritin. PLoS One. 2015; 10:e0125291. PMID: 25993535.
23. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol. 2006; 133:9–29. PMID: 16622281.
24. D'souza N, Rossignoli F, Golinelli G, Grisendi G, Spano C, Candini O, et al. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. BMC Med. 2015; 13:186. PMID: 26265166.
25. Corot C, Robert P, Idée JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58:1471–1504. PMID: 17116343.
26. Bach-Gansmo T. Ferrimagnetic susceptibility contrast agents. Acta Radiol Suppl. 1993; 387:1–30. PMID: 8390776.
27. Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011; 1:35–40. PMID: 23256052.
28. de Rochefort L, Liu T, Kressler B, Liu J, Spincemaille P, Lebon V, et al. Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: validation and application to brain imaging. Magn Reson Med. 2010; 63:194–206. PMID: 19953507.
29. Eibofner F, Steidle G, Kehlbach R, Bantleon R, Schick F. Positive contrast imaging of iron oxide nanoparticles with susceptibility-weighted imaging. Magn Reson Med. 2010; 64:1027–1038. PMID: 20564596.